CA-ANDERSEN-GLOBAL
18.12.2020 10:41:14 CET | Business Wire | Pressemeddelelse
Andersen Global fortsætter med at udvide sin europæiske dækning gennem en samarbejdsaftale med advokatfirmaet Chetcuti Cauchi Advocates og det tilknyttede firma, der leverer virksomhedstjenester, CCA Interserv Ltd , beliggende i Valletta, Malta.
Chetcuti Cauchi, anerkendt af Chambers and Partners , Legal 500 og IFLR1000 , betjener iværksættere, familievirksomheder og institutioner med lokale og internationale behov. Ledet af administrerende partner Jean-Philippe Chetcuti leverer firmaet et komplet spektrum af juridiske, skatte-, selskabs-, immigrations- og forvaltningstjenester til kunder, med specialiseringer inden for selskabsret, skatteret, opholdstilladelse og statsborgerskab, finansielle tjenester, fintech, fast ejendom, sø- og luftfartslovgivning.
”Vi har forpligtet os til at være et markedsførende firma og tilbyde vores kunder omfattende juridiske, selskabs- og skattetjenester inden for forskellige brancher," sagde Jean-Philippe. ”Andersen Globals kundedrevne tilgang og forpligtelse til at levere uovertrufne tjenester stemmer overens med vores firmas filosofi. Vi er overbeviste om, at dette samarbejde vil bringe sømløse løsninger til vores kunder lokalt og i udlandet.”
”Chetcuti Cauchi Advocates har allerede etableret synergistiske samarbejdsrelationer med flere af vores medlemsfirmaer og samarbejdsfirmaer i regionen,” sagde bestyrelsesformand for Andersen Global og administrerende direktor for Andersen, Mark Vorsatz. ”Ud over vores fælles værdier har de stor ekspertise og forståelse af det lokale marked. Dette samarbejde styrker vores tilstedeværelse i regionen yderligere og positionerer os til fremtidig vækst.”
Andersen Global er en international sammenslutning af juridisk adskilte, uafhængige medlemsfirmaer bestående af skatte- og juraeksperter fra hele verden. Efter at være blevet etableret i 2013 af det amerikanske medlemsfirma Andersen Tax LLC har Andersen Global nu over 6.000 eksperter globalt og er repræsenteret på mere end 227 lokaliteter via sine medlems- og samarbejdsfirmaer.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20201218005203/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin6.8.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today it is working with the U.S. Department of Verterans Affairs (VA) on a multi-site randomized controlled clinical trial. The study will evaluate the safety and efficacy of COMP360 psilocybin in the treatment of treatment-resistant depression (TRD) in veterans, including those with concurrent post-traumatic stress disorder (PTSD). The trial, titled "Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression," or PIVOT, reflects VA’s commitment to pursuing innovative solutions for veterans who have not responded to existing treatments. Compass will donate the study drug - COMP360, a synthetic, proprietary pharmaceutical-grade formulation of psilocybin optimized for stability and purity. Compass will support the education and training of the investigators and their training team through the provision of training
Great Britain Leads Europe’s FMCG Inflation as NIQ Launches New Inflation Barometer6.8.2026 09:00:00 CEST | Press release
NIQ (NYSE: NIQ) today launches its new EU5 FMCG Inflation Barometer - a monthly tracker across five Western Europe markets – France, Great Britain, Germany, Italy and Spain – designed to help retailers, manufacturers and the media understand how inflation is evolving across Europe’s largest grocery markets and how shoppers are responding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806579111/en/ EU5 CPG Inflation slows to +1.1% The first edition of the Barometer reveals that while inflation across Europe’s FMCG sector remains relatively contained overall, significant differences persist between countries. Key findings include: Great Britain recorded the highest FMCG inflation across the EU5 at +2.3%1, above the European average of +1.1%. France and Italy reported the lowest inflation at -0.4% and +0.6% retrospectively, highlighting the uneven inflationary landscape across Europe's major economies. The monthly Barometer
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum